Chiusura precedente | 4,9900 |
Aperto | 5,0200 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 4,8400 - 5,0200 |
Intervallo di 52 settimane | 4,7600 - 100,8000 |
Volume | |
Media Volume | 13.221 |
Capitalizzazione | 7,668M |
Beta (5 anni mensile) | 0,70 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -43,6800 |
Prossima data utili | 13 mag 2024 - 17 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced it has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company’s Board of Direct
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells Successfully applied in proof-of-concept evaluation by OmniAb to select antibodies against ion channel and chemokine receptor proteins in transgenic animals ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present data